Boston, MA 01/13/2013 (wallstreetpr) – That Mannkind Corporation (NASDAQ:MNKD) is becoming a pendulum is causing anxiety somewhere. There isn’t so much that one can say about this stock now except about what investors can expect in the few coming months.
Of late the stock soars and pulls back without warning and there is nothing strange about this as it happens with almost every stock. The question we should be asking is whether these up and down rally of the stock suggest anything beyond what the eye can see. I think it is important keeping a tab on this stock because it has entered into what one may call psychological trading.
Considering that Mannkind Corporation (NASDAQ:MNKD) jumped almost 18 percent on Thursday last week and closed the week at 16.38 percent in red ink suggest that investors are trading the stock with an eye on its clinical candidate Afrezza.
FDA Advisory Committee is expected to opening its review on Afrezza on April 1 and the review is expected to complete by April 15. It comes as good news that the Committee will be taking another look at the drug. However, nobody is sure what results to expect from the review, this is why investors are cautious trading the stock, thus sending it up and down quite often.
FDA Advisory Committee decision
Knowing what the FDA committee is going to say about Afrezza is important in making informed investment decision on this stock. But can we read the mind of the Committee? Personally I think the Committee is going to give the drug a green-light. My thinking is based around the strength of the drug’s late stage trial results.
Performance
However, knowing what the Committee is going to day about Afrezza is just half of what investors need to know about the future prospects of Mannkind Corporation (NASDAQ:MNKD). The other half is about how the drug stands to perform in the market.
The drug will be vying for the market against injectable pens offered by Eli Lilly and Novo Nordisk. Perhaps the fact that Mannkind Corporation (NASDAQ:MNKD) is presenting inhalable insulin product could be a compelling aspect to put the company at the top of the market and this will obviously strengthen the stock going forward.
